BBT-002

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameBBT-002
Drug Alias NameBBT-002BBT002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Skin DiseasesNasal Polyps +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBambusa Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanzhuyao (Beijing) Biomedical Technology Co LtdBambusa Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Skin DiseasesNasal Polyps +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A